NOS2 and breast carcinoma: Since azole-containing molecules have demonstrated activity towards this enzyme both as substrate analogues and dimerisation inhibitors16 and based on our ongoing efforts in the research of new molecules able to inhibit iNOS17,18, we evaluated compounds 2–8 and 13–20 as iNOS inhibitors, with the aim to ascertain their potential polypharmacological effects against breast cancer progression.